PMID: 20081867. 8. Andersen JT, Sandlie I. 2009. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

VRDN-008 is a half-life extended bispecific FcRn inhibitor comprising an Fc fragment and an albumin-binding domain designed to prolong IgG suppression and provide a potentially best-in-class ...

In the vast landscape of antibody drug development, the interaction between IgG and neonatal Fc receptor ( FcRn ) stands as an undeniable cornerstone. This interaction profoundly shapes the ...

Albumin binding to FcRn, GP60, and SPARC results in an improved PK profile, decreased toxicity risk, and a broader therapeutic index preclinically, with significant targeting of the tumor ...

Immunovant’s IMVT-1402 is highlighted as the most convenient FcRn inhibitor in late-stage development, featuring an easy-to-use subcutaneous auto-injector. The drug’s potential for deeper IgG ...

There were no clinically significant increases in ALT/AST or bilirubin, no clinically significant reductions in albumin and no clinically ... antibodies targeting FcRn inhibition, offering a ...